JP2014503528A5 - - Google Patents

Download PDF

Info

Publication number
JP2014503528A5
JP2014503528A5 JP2013543881A JP2013543881A JP2014503528A5 JP 2014503528 A5 JP2014503528 A5 JP 2014503528A5 JP 2013543881 A JP2013543881 A JP 2013543881A JP 2013543881 A JP2013543881 A JP 2013543881A JP 2014503528 A5 JP2014503528 A5 JP 2014503528A5
Authority
JP
Japan
Prior art keywords
compound
alkyl
formula
use according
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013543881A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014503528A (ja
Filing date
Publication date
Priority claimed from GBGB1021161.3A external-priority patent/GB201021161D0/en
Priority claimed from GBGB1109162.6A external-priority patent/GB201109162D0/en
Application filed filed Critical
Priority claimed from PCT/GB2011/052475 external-priority patent/WO2012080729A2/en
Publication of JP2014503528A publication Critical patent/JP2014503528A/ja
Publication of JP2014503528A5 publication Critical patent/JP2014503528A5/ja
Pending legal-status Critical Current

Links

JP2013543881A 2010-12-14 2011-12-14 カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用 Pending JP2014503528A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1021161.3A GB201021161D0 (en) 2010-12-14 2010-12-14 Casein kinase 1delta (CK1Delta) inhibitors
GB1021161.3 2010-12-14
GB1109162.6 2011-06-01
GBGB1109162.6A GB201109162D0 (en) 2011-06-01 2011-06-01 Casein kinase 1Delta (CK1Delta) inhibitors
PCT/GB2011/052475 WO2012080729A2 (en) 2010-12-14 2011-12-14 CASEIN KINASE 1δ (CK1δ) INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016175298A Division JP2017025080A (ja) 2010-12-14 2016-09-08 カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用

Publications (2)

Publication Number Publication Date
JP2014503528A JP2014503528A (ja) 2014-02-13
JP2014503528A5 true JP2014503528A5 (cg-RX-API-DMAC7.html) 2014-12-25

Family

ID=45444638

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013543881A Pending JP2014503528A (ja) 2010-12-14 2011-12-14 カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
JP2013543879A Expired - Fee Related JP5937102B2 (ja) 2010-12-14 2011-12-14 カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
JP2016095027A Active JP6243472B2 (ja) 2010-12-14 2016-05-11 カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
JP2016175298A Withdrawn JP2017025080A (ja) 2010-12-14 2016-09-08 カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2013543879A Expired - Fee Related JP5937102B2 (ja) 2010-12-14 2011-12-14 カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
JP2016095027A Active JP6243472B2 (ja) 2010-12-14 2016-05-11 カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
JP2016175298A Withdrawn JP2017025080A (ja) 2010-12-14 2016-09-08 カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用

Country Status (10)

Country Link
US (5) US20140031547A1 (cg-RX-API-DMAC7.html)
EP (3) EP2651404B1 (cg-RX-API-DMAC7.html)
JP (4) JP2014503528A (cg-RX-API-DMAC7.html)
CN (3) CN105920010A (cg-RX-API-DMAC7.html)
AU (2) AU2011343039B2 (cg-RX-API-DMAC7.html)
CA (1) CA2818903C (cg-RX-API-DMAC7.html)
DK (1) DK2835131T3 (cg-RX-API-DMAC7.html)
ES (2) ES2650744T3 (cg-RX-API-DMAC7.html)
HK (1) HK1214527A1 (cg-RX-API-DMAC7.html)
WO (2) WO2012080729A2 (cg-RX-API-DMAC7.html)

Families Citing this family (237)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
CN104926815B (zh) 2008-01-04 2017-11-03 英特利凯恩有限责任公司 某些化学实体、组合物和方法
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
PL2448938T3 (pl) 2009-06-29 2014-11-28 Incyte Holdings Corp Pirymidynony jako inhibitory PI3K
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011123609A1 (en) * 2010-03-31 2011-10-06 Glaxo Group Limited Imidazolyl-imidazoles as kinase inhibitors
CA2796311A1 (en) 2010-04-14 2011-10-20 Incyte Corporation Fused derivatives as pi3k.delta. inhibitors
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
JP2014503528A (ja) * 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
CA2822070C (en) 2010-12-20 2019-09-17 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
AR084824A1 (es) 2011-01-10 2013-06-26 Intellikine Inc Procesos para preparar isoquinolinonas y formas solidas de isoquinolinonas
WO2012125629A1 (en) 2011-03-14 2012-09-20 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
PH12021552978A1 (en) 2011-09-02 2022-08-22 Incyte Holdings Corp Heterocyclylamines as pi3k inhibitors
UA115133C2 (uk) 2011-10-07 2017-09-25 Такеда Фармасьютікал Компані Лімітед Сполуки 1-арилкарбоніл-4-оксипіперидину, придатні для лікування нейродегенеративних захворювань
PH12014500820A1 (en) 2011-10-18 2014-05-19 Astellas Pharma Inc Bicyclic heterocyclic compound
AR090037A1 (es) 2011-11-15 2014-10-15 Xention Ltd Derivados de tieno y/o furo-pirimidinas y piridinas inhibidores de los canales de potasio
KR102000770B1 (ko) 2011-12-01 2019-07-16 케모센트릭스, 인크. Ｃｃｒ(4) 길항제로서의 치환된 아닐린
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
EP3495367B1 (en) 2012-06-13 2020-09-30 Incyte Holdings Corporation Substituted tricyclic compounds as fgfr inhibitors
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
JP6299591B2 (ja) * 2012-07-03 2018-03-28 小野薬品工業株式会社 ソマトスタチン受容体作動活性を有する化合物およびその医薬用途
WO2014009891A1 (en) * 2012-07-11 2014-01-16 Piramal Enterprises Limited Heterocyclic compounds for use in the treatment of cancers
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
CN113679717A (zh) * 2012-08-22 2021-11-23 康奈尔大学 用于抑制肌成束蛋白的方法
RU2641293C2 (ru) * 2012-08-24 2018-01-17 Тревентис Корпорейшн Бензофуразановые антимилоидные соединения и способы
CN102850341B (zh) * 2012-09-05 2015-02-18 浙江工业大学 一种噻二唑类化合物及其制备与应用
GB201216018D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Pharmacologically active compounds
ES2753163T3 (es) 2012-09-25 2020-04-07 Hoffmann La Roche Derivados de hexahidropirrolo[3,4-c]pirrol y compuestos relacionados como inhibidores de la autotaxina (ATX) y como inhibidores de la producción de ácido lisofosfatídico (LPA) para tratar, por ejemplo, enfermedades renales
CN103739594A (zh) * 2012-10-17 2014-04-23 南京大学 一类含吡嗪环和三氮唑结构的席夫碱类衍生物及其制法
HRP20181367T4 (hr) 2012-11-01 2021-11-26 Infinity Pharmaceuticals, Inc. Liječenje raka korištenjem modulatora izoforme pi3 kinaze
WO2014084778A1 (en) 2012-11-27 2014-06-05 Thomas Helledays Stiftelse För Medicinsk Forskning Pyrimidine-2,4-diamine derivatives for treatment of cancer
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
JP6284490B2 (ja) * 2012-12-28 2018-02-28 株式会社新日本科学 イミダゾピリジン誘導体を有効成分として含むｏｃｔ３活性阻害剤又はｏｃｔ３検出剤
NZ710444A (en) * 2013-02-11 2020-08-28 Univ California Compositions and methods for treating neurodegenerative diseases and cardiomyopathy
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
EP2970306A4 (en) 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
EP2967046A4 (en) 2013-03-15 2016-12-21 Whitehead Inst Biomedical Res BENZIMIDAZOLE DERIVATIVES AND USES THEREOF
DK2986610T5 (en) 2013-04-19 2018-12-10 Incyte Holdings Corp BICYCLIC HETEROCYCLES AS FGFR INHIBITORS
US9797882B2 (en) 2013-07-09 2017-10-24 The Translational Genomics Research Institute Method of screening for a compound for inhibitory activity of FN14-tweak interaction
US9238034B2 (en) * 2013-07-09 2016-01-19 The Translational Genomics Research Institute FN14 antagonists and therapeutic uses thereof
TWI649308B (zh) 2013-07-24 2019-02-01 小野藥品工業股份有限公司 喹啉衍生物
GB201314452D0 (en) 2013-08-13 2013-09-25 Ostara Biomedical Ltd Embryo implantation
RU2570907C2 (ru) * 2013-10-21 2015-12-20 Автономная Некоммерческая Организация "Научно-Исследовательский Центр Биотехнологии Антибиотиков И Других Биологически Активных Веществ "Биоан" Производные 3-ациламинопиридин-2(1h)-она, применимые как ингибиторы серин-треониновой протеинкиназы gsk3b в качестве лекарственных препаратов для лечения диабета ii типа.
JP6502939B2 (ja) 2013-11-22 2019-04-17 シーエル バイオサイエンシズ リミティド ライアビリティ カンパニー 骨粗鬆症の処置及び予防のためのガストリン拮抗薬
CA2923523A1 (en) 2013-11-26 2015-06-04 F. Hoffmann-La Roche Ag New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl
GB201321738D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
EP3091984B1 (en) * 2014-01-09 2020-04-22 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Substituted benzoxazine and related compounds
UA118369C2 (uk) 2014-01-29 2019-01-10 Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед Сполуки, що інгібують активність lrrk2 кінази
WO2015113451A1 (en) 2014-01-29 2015-08-06 Glaxosmithkline Intellectual Property Development Limited Compounds
AU2015217152A1 (en) 2014-02-11 2016-08-11 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
CN106164066B (zh) 2014-02-13 2020-01-17 因赛特公司 作为lsd1抑制剂的环丙胺
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Ｌｓｄ１阻害剤としてのシクロプロピルアミン類
US9573946B2 (en) 2014-02-20 2017-02-21 Novita Pharmaceuticals, Inc. Compounds and methods for inhibiting fascin
DK3110812T3 (da) * 2014-02-27 2019-07-08 Treventis Corp Anti-amyloidforbindelser indeholdende benzofurazan
JP6554481B2 (ja) 2014-03-26 2019-07-31 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ オートタキシン（ａｔｘ）及びリゾホスファチジン酸（ｌｐａ）産生の阻害剤としての縮合［１，４］ジアゼピン化合物
SG11201607839UA (en) 2014-03-26 2016-10-28 Hoffmann La Roche Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN106164059A (zh) * 2014-04-11 2016-11-23 爱默蕾大学 用天冬酰胺内肽酶（aep）抑制剂以及相关组合物对神经退行性疾病的治疗
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
CN105085436B (zh) * 2014-04-19 2019-08-16 广东东阳光药业有限公司 磺酰胺类衍生物及其在药物上的应用
HUE057317T2 (hu) 2014-04-23 2022-04-28 Dart Neuroscience Llc Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
CN104059060B (zh) * 2014-05-30 2017-08-01 西安交通大学 一种5‑(1h‑吲哚‑3‑亚甲基)‑1,3‑噻唑烷‑4‑酮类衍生物及其合成方法和应用
US10064869B2 (en) 2014-06-04 2018-09-04 Thomas Helledays Stiftelse For Medicinsk Forskning MTH1 inhibitors for treatment of inflammatory and autoimmune conditions
CA2949785A1 (en) 2014-06-04 2015-12-10 Thomas Helledays Stiftelse For Medicinsk Forskning Mth1 inhibitors for treatment of cancer
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EP3174877B1 (en) * 2014-07-31 2022-06-29 Merck Patent GmbH Indolizine derivatives which are applicable to neurodegenerative diseases
EP3189070A4 (en) 2014-08-04 2018-06-27 Drexel University Novel compounds and methods of treating or ameliorating an il-1r-mediated disease or disorder using same
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
JP6746569B2 (ja) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
GB201419579D0 (en) * 2014-11-03 2014-12-17 Iomet Pharma Ltd Pharmaceutical compound
US10239882B2 (en) 2014-11-05 2019-03-26 Dart Neuroscience (Cayman) Ltd. Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors
US10208034B2 (en) 2014-12-25 2019-02-19 Ono Pharmaceutical Co., Ltd. Quinoline derivative
GB201501302D0 (en) 2015-01-27 2015-03-11 Ostara Biomedical Ltd Embryo implantation
CR20170390A (es) 2015-02-20 2017-10-23 Incyte Holdings Corp Heterociclos biciclicos como inhibidores de fgfr
WO2016134294A1 (en) 2015-02-20 2016-08-25 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
LT3262046T (lt) 2015-02-27 2021-01-11 Incyte Corporation Pi3k inhibitoriaus druskos ir jų gamybos būdai
CN113350353A (zh) * 2015-03-23 2021-09-07 墨尔本大学 呼吸性疾病的治疗
CN107660205B (zh) 2015-04-03 2021-08-27 因赛特公司 作为lsd1抑制剂的杂环化合物
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
US10370328B2 (en) * 2015-04-30 2019-08-06 Musc Foundation For Research Development Oxindole compounds and pharmaceutical compositions thereof
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
WO2016183060A1 (en) 2015-05-11 2016-11-17 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
GB201508276D0 (en) 2015-05-14 2015-06-24 Electrophoretics Ltd A casein kinase 1 delta inhibitor
GB201509134D0 (en) 2015-05-28 2015-07-15 Electrophoretics Ltd Biomolecules involved in Alzheimer's disease
BR112017025851A2 (pt) * 2015-06-01 2018-10-16 Bantam Pharmaceutical, Llc compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo
WO2016202756A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
WO2016202758A1 (en) 2015-06-18 2016-12-22 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-1h-benzimidazole compounds
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
CN108290855A (zh) * 2015-07-01 2018-07-17 西北大学 被取代的喹唑啉化合物及其调节葡糖脑苷脂酶活性的用途
EA035534B1 (ru) 2015-08-12 2020-06-30 Инсайт Корпорейшн Соли ингибитора lsd1
CN105061462B (zh) * 2015-08-18 2017-05-24 沈阳药科大学 含有酰胺的四氢苯并[4,5]噻吩并[2,3‑d]嘧啶类化合物及其应用
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
CA2997537C (en) 2015-09-18 2024-02-13 Kaken Pharmaceutical Co., Ltd. Biaryl derivative and medicine containing same
CA2983782A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
JP6877413B2 (ja) 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重ａｔｘ／ｃａ阻害剤としての新規な二環式化合物
EP3353181B1 (en) 2015-09-24 2021-08-11 F. Hoffmann-La Roche AG Bicyclic compounds as dual atx/ca inhibitors
WO2017050792A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
GB201517523D0 (en) 2015-10-05 2015-11-18 Ostara Biomedical Ltd Methods and compositions for managing reproduction
WO2017062500A2 (en) 2015-10-05 2017-04-13 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
WO2017063966A1 (en) 2015-10-13 2017-04-20 Bayer Pharma Aktiengesellschaft Substituted 2-(1h-pyrazol-1-yl)-benzothiazole compounds
CN108349979B (zh) * 2015-11-02 2021-04-09 詹森药业有限公司 [1,2,4]三唑并[1,5-a]嘧啶-7-基化合物
ES2926781T3 (es) * 2015-12-07 2022-10-28 Hinova Pharmaceuticals Inc Compuestos de quinoleína, método de preparación de los mismos, y uso de los mismos como fármaco inhibidor del transportador de urato
WO2017106367A1 (en) * 2015-12-15 2017-06-22 D.E. Shaw Research, Llc Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity
CN107840826B (zh) * 2016-09-19 2021-07-09 西华大学 1h-吲唑类衍生物及其作为ido抑制剂的用途
CN107033087B (zh) * 2016-02-04 2020-09-04 西华大学 1h-吲唑-4-胺类化合物及其作为ido抑制剂的用途
WO2017133258A1 (zh) * 2016-02-04 2017-08-10 西华大学 1h-吲唑类衍生物及其作为ido抑制剂的用途
BR112018071585B1 (pt) 2016-04-22 2024-01-02 Incyte Corporation Formulações de um inibidor de lsd1, seus usos e método de preparação das mesmas
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
KR20230109185A (ko) 2016-06-07 2023-07-19 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
US10906888B2 (en) 2016-07-14 2021-02-02 Pfizer Inc. Pyrimidine carboxamides as inhibitors of Vanin-1 enzyme
ES2901059T3 (es) * 2016-08-09 2022-03-21 Zincure Corp Composición farmacéutica para el tratamiento de apoplejía basado en la inhibición de AMPK
WO2018033918A1 (en) 2016-08-18 2018-02-22 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
TWI750218B (zh) 2016-09-02 2021-12-21 美商賽克瑞恩醫療公司 sGC 刺激劑
CN106432235B (zh) * 2016-10-19 2018-02-02 南通大学 靶向CDK和DNA的β‑咔啉衍生物及其制备方法和医药用途
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
WO2018083103A1 (en) 2016-11-02 2018-05-11 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as pde2 inhibitors
EA039847B1 (ru) 2016-11-02 2022-03-18 Янссен Фармацевтика Нв СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
MY193511A (en) * 2016-11-02 2022-10-17 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
EP3538101B1 (en) 2016-11-14 2024-06-19 Virginia Commonwealth University Inhibitors of cancer and/or metastasis
EP3541378A4 (en) * 2016-11-16 2020-10-07 University of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6A AND THEIR USE IN THE MITIGATION OF PROTEINOPATHIES
CN110392833A (zh) 2017-01-06 2019-10-29 优曼尼蒂治疗公司 治疗神经病症的方法
CN110494136A (zh) * 2017-01-10 2019-11-22 瑞士苏黎世联邦理工学院 细胞保护性化合物及其用途
CN106831573B (zh) * 2017-01-23 2019-05-24 南阳师范学院 (n-1,2,3,4-四氢异喹啉基)-阿魏酰胺化合物、制备方法及其应用
CN106748969B (zh) * 2017-01-23 2019-06-18 南阳师范学院 一种n-(4-苄基哌啶基)-阿魏酰胺化合物、制备方法及其用途
PL3571193T3 (pl) 2017-01-23 2022-04-25 Cadent Therapeutics, Inc. Modulatory kanału potasowego
JP6605763B2 (ja) 2017-01-26 2019-11-13 小野薬品工業株式会社 キノリン誘導体のエタンスルホン酸塩
ES2902885T3 (es) * 2017-02-01 2022-03-30 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Derivados de N1-(4-(5-(ciclopropilmetil)-1-metil-1H-pirazol-4-il)piridin-2-il)ciclohexano-1,4-diamina y compuestos relacionados como inhibidores de CK1 y/o IRAK1 para el tratamiento del cáncer
CN109700798A (zh) * 2017-03-01 2019-05-03 浙江大学 苯并吡喃黄酮结构类型雄激素受体拮抗剂及其应用
KR20190129924A (ko) 2017-03-16 2019-11-20 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 유용한 헤테로환형 화합물
WO2018167113A1 (en) 2017-03-16 2018-09-20 F. Hoffmann-La Roche Ag New bicyclic compounds as atx inhibitors
ES2788856T3 (es) 2017-03-20 2020-10-23 Forma Therapeutics Inc Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR)
PT3601239T (pt) 2017-03-23 2024-10-24 Jacobio Pharmaceuticals Co Ltd Novos derivados heterocíclicos úteis como inibidores de shp2
JP7191298B2 (ja) 2017-04-26 2022-12-19 バジリア・ファルマスーチカ・インターナショナル・アーゲー，アルシュヴィル フラザノベンズイミダゾール類及びその結晶形の調製方法
US11136312B2 (en) * 2017-05-12 2021-10-05 Board of Trustees of the Southern Illinois University 3,4,5-trisubstituted-1,2,4-triazoles and 3,4,5-trisubstituted-3-thio-1,2,4-triazoles and uses thereof
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
JP2020523379A (ja) * 2017-06-14 2020-08-06 ヨーロピアン モレキュラー バイオロジー ラボラトリーＥｕｒｏｐｅａｎ Ｍｏｌｅｃｕｌａｒ Ｂｉｏｌｏｇｙ Ｌａｂｏｒａｔｏｒｙ 治療への使用のためのベンゾフランアミドおよびそれらの複素芳香族アナログ
AU2018290225A1 (en) 2017-06-21 2020-01-23 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
GB201710851D0 (en) * 2017-07-06 2017-08-23 Galápagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
KR102656934B1 (ko) 2017-07-10 2024-04-16 셀진 코포레이션 항증식성 화합물 및 이의 사용 방법
ES3008911T3 (en) 2017-07-11 2025-03-25 Vertex Pharma Carboxamides as modulators of sodium channels
WO2019049965A1 (ja) * 2017-09-11 2019-03-14 保土谷化学工業株式会社 ピリミジン環構造を有する化合物および有機エレクトロルミネッセンス素子
CA3075880A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors
US11826363B2 (en) 2017-10-13 2023-11-28 Ono Pharmaceutical Co., Ltd. Therapeutic agent for solid cancers, which comprises Axl inhibitor as active ingredient
WO2019079578A1 (en) 2017-10-19 2019-04-25 Amgen Inc. BENZIMIDAZOLE DERIVATIVES AND USES THEREOF
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
US20200325148A1 (en) * 2017-12-21 2020-10-15 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
CA3083368A1 (en) * 2017-12-21 2019-06-27 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
CA3092470A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
US20210040074A1 (en) * 2018-03-06 2021-02-11 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Positive allosteric modulators of dopamine 1 receptor and method of use thereof
EP3543231A1 (en) * 2018-03-19 2019-09-25 ETH Zurich Compounds for treating cns- and neurodegenerative diseases
AU2019238326B2 (en) 2018-03-23 2025-03-06 Janssen Pharmaceutica Nv Compounds and uses thereof
US11466004B2 (en) 2018-05-04 2022-10-11 Incyte Corporation Solid forms of an FGFR inhibitor and processes for preparing the same
CN112566912A (zh) 2018-05-04 2021-03-26 因赛特公司 Fgfr抑制剂的盐
TWI815887B (zh) * 2018-05-15 2023-09-21 美商愛彼特生物製藥股份有限公司 經取代的2,2'-雙嘧啶基化合物、其類似物及其使用方法
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CA3101323A1 (en) 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
MX2023013508A (es) 2018-06-29 2023-12-13 Forma Therapeutics Inc Inhibicion de la proteina de union a creb (cbp).
AU2019297361B2 (en) 2018-07-05 2024-06-27 Incyte Corporation Fused pyrazine derivatives as A2A / A2B inhibitors
US12195432B2 (en) * 2018-08-06 2025-01-14 The Board Of Trustees Of The Leland Stanford Junior University 2-arylbenzimidazoles as Ppargc1a activators for treating neurodegenerative diseases
WO2020047030A1 (en) 2018-08-29 2020-03-05 Chemocentryx, Inc. Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020051206A1 (en) * 2018-09-04 2020-03-12 Brown University Compositions and methods for the modulation of crfbp and the treatment of alcoholism
FI3853234T3 (fi) 2018-09-18 2025-07-28 Nikang Therapeutics Inc Fuusioituja trisyklisiä rengasjohdannaisia SRC-homologia-2-fosfataasin estäjinä
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
CN112839935A (zh) 2018-09-26 2021-05-25 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
BR112021007552A2 (pt) 2018-10-22 2021-07-27 Cadent Therapeutics, Inc. formas cristalinas de moduladores de canal de potássio
WO2020086504A1 (en) * 2018-10-23 2020-04-30 Daiichi Sankyo Company, Limited Biaryl derivative
EP3877383A4 (en) 2018-11-07 2022-09-21 The University of Melbourne COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY DISEASES
CN109503563B (zh) * 2018-12-10 2020-05-12 济南大学 多功能乙酰胆碱酯酶抑制剂及其应用
KR102128509B1 (ko) * 2018-12-19 2020-07-01 한국과학기술연구원 말단 아민기에 아릴 또는 헤테로아릴기가 치환된 신규한 히드라존 유도체 및 이의 용도
JP7507162B2 (ja) * 2019-01-04 2024-06-27 ベルブルック ラボズ，エルエルシー 治療薬としてのｃＧＡＳ活性の阻害剤
WO2020146612A1 (en) 2019-01-10 2020-07-16 Vertex Pharmaceuticals Incorporated Esters and carbamates as modulators of sodium channels
US12441703B2 (en) 2019-01-10 2025-10-14 Vertex Pharmaceuticals Incorporated Carboxamides as modulators of sodium channels
MA54829A (fr) 2019-01-24 2021-12-01 Yumanity Therapeutics Inc Composés et leurs utilisations
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
WO2020185532A1 (en) 2019-03-08 2020-09-17 Incyte Corporation Methods of treating cancer with an fgfr inhibitor
EP3937940A4 (en) 2019-03-15 2022-12-21 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
JP7546596B2 (ja) * 2019-04-26 2024-09-06 セルジーン コーポレーション ヘテロ環式化合物ならびに蠕虫感染および疾患におけるその使用
UY38687A (es) 2019-05-17 2023-05-15 Novartis Ag Inhibidores del inflamasoma nlrp3, composiciones, combinaciones de los mismos y métodos para su uso
RS64931B9 (sr) 2019-06-18 2025-06-30 Pfizer Derivati benzizoxazol sulfonamida
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
JP7721501B2 (ja) 2019-07-31 2025-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３８の阻害剤としてのヘテロ二環式アミド
RU2746423C2 (ru) * 2019-09-02 2021-04-13 Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") Ингибитор вируса гепатита В (ВГВ)
MA57202B1 (fr) 2019-09-19 2025-09-30 Novo Nordisk Health Care Ag Compositions d'activation de la pyruvate kinase r (pkr)
US12122767B2 (en) 2019-10-01 2024-10-22 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN114929217A (zh) 2019-11-14 2022-08-19 锌医疗公司 基于ampk抑制功能和锌稳态控制功能用于治疗多发性硬化的药物组合物
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
EP4069696A1 (en) 2019-12-04 2022-10-12 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
PT4069691T (pt) 2019-12-06 2024-12-18 Vertex Pharma Tetrahidrofuranos substituídos como moduladores dos canais de sódio
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
AR122711A1 (es) * 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA
US20230265082A1 (en) * 2020-08-10 2023-08-24 Dana-Farber Cancer Institute, Inc. Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
KR20230069169A (ko) * 2020-09-17 2023-05-18 얀센 파마슈티카 엔.브이. 카제인 키나제 1 델타 조절제
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
GB202101734D0 (en) * 2021-02-08 2021-03-24 Cerevance Inc Novel Compounds
AU2022222470A1 (en) 2021-02-19 2023-09-21 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
EP4294807A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
KR20230146639A (ko) * 2021-04-21 2023-10-19 장춘 진사이언스 파마슈티컬 씨오., 엘티디. 이미다졸 함유 축합고리계 유도체, 이의 제조방법 및 이의 의약적 용도
GEAP202416430A (en) 2021-06-04 2024-03-25 Vertex Pharma N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels
WO2022261159A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP2024522189A (ja) 2021-06-09 2024-06-11 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての三環式ヘテロ環
CA3233233A1 (en) * 2021-10-15 2023-04-20 Ruben Abagyan Substituted 1h-pyrazolo [4,3-c] quinolines, methods of preparation, and use thereof
CN119677737A (zh) 2022-04-22 2025-03-21 沃泰克斯药物股份有限公司 用于治疗疼痛的杂芳基化合物
CN115466211B (zh) * 2022-06-09 2024-02-23 中国人民解放军空军军医大学 一种n-苯基喹啉-4-胺类化合物及其应用
CN119497615A (zh) * 2022-07-14 2025-02-21 上海日馨医药科技股份有限公司 Tpk激动剂及使用其治疗神经退行性疾病的方法
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
TW202428579A (zh) * 2022-10-19 2024-07-16 大陸商長春金賽藥業有限責任公司 Ｎｋ３ｒ拮抗劑的晶型及其製備方法和用途
EP4646263A1 (en) * 2023-01-20 2025-11-12 Allianthera (Suzhou) Biopharmaceutical Co., Ltd. Sprk1 inhibitors and methods of use
AR131690A1 (es) * 2023-01-30 2025-04-23 Eurofarma Laboratorios S A COMPUESTOS FENÓLICOS BLOQUEADORES DE Nav 1.7 Y/O Nav 1.8, SUS PROCESOS DE OBTENCIÓN, SUS COMPOSICIONES, SUS USOS, LOS MÉTODOS DE TRATAMIENTO DE LOS MISMOS Y LOS KITS
EP4660182A1 (en) * 2023-01-30 2025-12-10 Eurofarma Laboratórios S.A. Nav1.7- and/or nav1.8-inhibiting aryl pyridine compounds, processes for the preparation thereof, compositions, uses, methods for treatment using same, and kits
CN118666857B (zh) * 2024-06-26 2025-02-25 江西农业大学 一种喹啉类化合物及其在农用杀菌剂中的应用
CN119060061B (zh) * 2024-08-26 2025-09-16 浙江师范大学 一类苯并嘧啶硫醚类化合物作为sting蛋白小分子抑制剂的应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
US20030219427A1 (en) * 1998-08-18 2003-11-27 Allen Hamish J. TPL-2/COT kinase and methods of use
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
US6087363A (en) * 1999-07-16 2000-07-11 Harbor Branch Oceanographic Institution, Inc. Use of imidazole and indole compounds as inhibitors of nitric oxide synthase
TR200402342T4 (tr) * 2000-09-01 2004-11-22 Mitsubishi Pharma Corporation 2-Pirindinil-6,7,8,9- Tetrahidropyrimido[1,2-A] Pirimidin-4-On ve 7-Pirindinil-1,3-Dihydoimidazo[1,2-A]Pirimidin-5(1H) on Türevleri
JP2004509115A (ja) * 2000-09-15 2004-03-25 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼインヒビターとして有用なピラゾール化合物
US7045539B2 (en) * 2000-12-22 2006-05-16 Astrazeneca Ab Therapeutic benzoxazole compounds
WO2003051833A2 (en) * 2001-12-18 2003-06-26 Merck & Co., Inc. Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
JP2003212859A (ja) * 2002-01-24 2003-07-30 Nippon Nohyaku Co Ltd 置換フェニルヘテロ環類及びこれを有効成分とする除草剤
US7405305B2 (en) * 2002-03-08 2008-07-29 Eli Lilly And Company Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors
FR2836915B1 (fr) * 2002-03-11 2008-01-11 Aventis Pharma Sa Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
WO2003097615A1 (en) * 2002-05-17 2003-11-27 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-β INHIBITORS
WO2003106439A1 (ja) * 2002-06-12 2003-12-24 株式会社ビーエフ研究所 アミロイド蓄積性疾患の画像診断プローブ化合物、老人斑／びまん性老人斑染色用化合物、ならびにアミロイド蓄積性疾患の治療薬
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu
US7060698B2 (en) * 2003-05-19 2006-06-13 Hoffmann-La Roche Inc. Benzoxazepinone derivatives
US20060241150A1 (en) * 2003-06-06 2006-10-26 Weiner David B P38 kinase inhibitor compositions and methods of using the same
GB0314943D0 (en) 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods
JP2007532669A (ja) * 2004-04-13 2007-11-15 イカジェン インコーポレイテッド カリウムイオンチャネル調節剤としての多環式ピリミジン
JP4931814B2 (ja) * 2004-08-19 2012-05-16 アベンティス・ファーマスーティカルズ・インコーポレイテツド カゼインキナーゼＩεの阻害剤としての３−アリールチオインドール−２−カルボキサミド誘導体及びその類似体
WO2007015866A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
EP1842541A1 (en) * 2006-03-29 2007-10-10 G.I.M.-Gesellschaft Für Innovative Medizin Gmbh Nfg Ohg Plant components and extracts and uses thereof
TW200813035A (en) * 2006-06-19 2008-03-16 Astrazeneca Ab Novel heteroaryl substituted benzoxazoles
BRPI0711674A2 (pt) * 2006-06-21 2011-11-16 Du Pont Método de inibição da proliferação indesejada, composto, composição e método de inibição
US7622495B2 (en) * 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
KR101176700B1 (ko) * 2006-11-02 2012-08-23 에프. 호프만-라 로슈 아게 미량 아민 결합된 수용체의 조절자로서 치환된 2-이미다졸
EP2081892A4 (en) * 2006-11-17 2014-03-05 Donald F Weaver COMPOUNDS AND METHOD FOR THE TREATMENT OF PROTEIN DISAPPEARANCE
ES2446269T3 (es) * 2006-12-19 2014-03-06 The Board Of Trustees Of The University Of Illinois 3-Benzofuranil-4-indolil-maleimidas como potentes inhibidores de GSK-3 para trastornos neurodegenerativos
US8445480B2 (en) * 2007-06-20 2013-05-21 Merck Sharp & Dohme Corp. CETP inhibitors derived from benzoxazole arylamides
FR2918061B1 (fr) * 2007-06-28 2010-10-22 Sanofi Aventis Derives de 6-cycloamino-3-(pyridin-4-yl)imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique.
FR2918986B1 (fr) * 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
GB0715939D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment of duchenne muscular dystrophy
CA2707076A1 (en) * 2007-11-28 2009-06-11 Yale University Nogo receptor binding small molecules to promote axonal growth
CA2709784A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
FR2934994B1 (fr) * 2008-08-12 2010-09-17 Sanofi Aventis Derives de 2-alkyl-6cycloamino-3-(pyridin-4-yl)imidaz°1,2-b! pyridazine, leur preparation et leur application en therapeutique
KR101257695B1 (ko) * 2008-12-24 2013-04-24 제일모직주식회사 신규한 유기광전소자용 화합물 및 이를 포함하는 유기광전소자
FR2945289A1 (fr) * 2009-05-11 2010-11-12 Sanofi Aventis Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
JP2013518046A (ja) * 2010-01-25 2013-05-20 シーエイチディーアイ ファウンデーション，インコーポレーテッド 特定のキヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法
JP2014503528A (ja) * 2010-12-14 2014-02-13 エレクトロプホレトイクス リミテッド カゼインキナーゼ１δ（ＣＫ１δ）阻害剤及びタウオパチーなどの神経変性疾患の治療におけるその使用
ES2773480T3 (es) 2011-05-09 2020-07-13 Eip Pharma Llc Composiciones y métodos para tratar la enfermedad de Alzheimer

Similar Documents

Publication Publication Date Title
JP2014503528A5 (cg-RX-API-DMAC7.html)
WO2012080729A4 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
JP2014503527A5 (cg-RX-API-DMAC7.html)
RU2423354C2 (ru) Соединения и композиции - модуляторы сигнального пути hedgehog
HRP20180916T1 (hr) Inhibitori demetilaze od lsd1 na bazi arilciklopropilamina i njihova medicinska uporaba
JP2018522823A5 (cg-RX-API-DMAC7.html)
RU2012143897A (ru) Замещенные пиримидины как антагонисты рецепторов простагландина d2
JP2020519606A5 (cg-RX-API-DMAC7.html)
JP2017533968A5 (cg-RX-API-DMAC7.html)
JP2016505614A5 (cg-RX-API-DMAC7.html)
RU2017134866A (ru) Соединения бензазепина дикарбоксамида
RU2008110949A (ru) Соединения и композиции-иммуносупрессанты
JP2008513516A5 (cg-RX-API-DMAC7.html)
JP2013535460A5 (cg-RX-API-DMAC7.html)
JP2009534386A5 (cg-RX-API-DMAC7.html)
JP2015517981A5 (cg-RX-API-DMAC7.html)
HUP0401876A2 (hu) Béta2 adrenerg receptor agonista hatású aril-anilin-származékok, valamint ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
RU2019121871A (ru) Новые производные фенилпропионовой кислоты и их применение
JP2015516429A5 (cg-RX-API-DMAC7.html)
JP2019506430A5 (cg-RX-API-DMAC7.html)
ME03723B (me) 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori
JP2012532125A5 (cg-RX-API-DMAC7.html)
JP2013509392A5 (cg-RX-API-DMAC7.html)
RU2015120556A (ru) Ингибиторы гликозидаз и их применения
RU2015102057A (ru) НОВЫЕ КОНДЕНСИРОВАННЫЕ ПИРИДИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ с-MET